AKYA insider transaction filings
Akoya Biosciences, Inc. — 20 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-07-10. Screen AKYA transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-07-10 | 4 | Ramachandran Niro Ph.D — Chief Business Officer | Other (J): 62,566 · Tax withholding (F): 42,148 · Other (J): 151,930 · Other (J): 130,625 · Other (J): 62,566 (derivative) @ $0 · Other (J): 45,000 (derivative) @ $0 · +2 more | EDGAR |
| 2025-07-10 | 4 | McKelligon Brian — President and CEO, Director | Other (J): 393,338 · Other (J): 331,090 · Tax withholding (F): 196,866 · Other (J): 947,688 · Other (J): 393,338 (derivative) @ $0 · Other (J): 331,090 (derivative) @ $0 · +4 more | EDGAR |
| 2025-07-10 | 4 | Kamocsay Jennifer — Chief Legal Officer | Other (J): 16,772 · Other (J): 162,500 · Other (J): 75,000 (derivative) @ $0 · Other (J): 70,000 (derivative) @ $0 | EDGAR |
| 2025-07-10 | 4 | Ek John Frederick — CFO | Other (J): 54,452 · Other (J): 193,750 · Other (J): 20,000 · Other (J): 160,000 (derivative) @ $0 · Other (J): 70,000 (derivative) @ $0 | EDGAR |
| 2025-07-10 | 4 | BAMFORD PASCAL — Chief Clinical Officer | Other (J): 9,488 · Other (J): 196,250 · Other (J): 150,000 (derivative) @ $0 · Other (J): 25,000 (derivative) @ $0 · Other (J): 15,000 (derivative) @ $0 · Other (J): 50,000 (derivative) @ $0 | EDGAR |
| 2025-07-10 | 4 | Winkler Matthew — Director | Other (J): 984,513 · Other (J): 16,860 (derivative) @ $0 · Other (J): 30,549 (derivative) @ $0 · Other (J): 56,322 (derivative) @ $0 · Other (J): 50,000 (derivative) @ $0 | EDGAR |
| 2025-07-10 | 4 | Mendel Scott — Director | Other (J): 28,500 · Other (J): 35,562 (derivative) @ $0 · Other (J): 30,549 (derivative) @ $0 · Other (J): 56,322 (derivative) @ $0 · Other (J): 44,959 (derivative) @ $0 · Other (J): 50,000 (derivative) @ $0 | EDGAR |
| 2025-07-10 | 4 | Raffin Thomas A. — Director | Other (J): 234,592 · Other (J): 1,737,712 · Other (J): 15,937,535 · Other (J): 16,860 (derivative) @ $0 · Other (J): 30,549 (derivative) @ $0 · Other (J): 56,322 (derivative) @ $0 · +1 more | EDGAR |
| 2025-07-10 | 4 | SCHNETTLER THOMAS P — Director | Other (J): 16,860 (derivative) @ $0 · Other (J): 30,549 (derivative) @ $0 · Other (J): 56,322 (derivative) @ $0 · Other (J): 50,000 (derivative) @ $0 | EDGAR |
| 2025-07-10 | 4 | LAI GOLDMAN MYLA — Director | Other (J): 20,000 · Other (J): 38,993 (derivative) @ $0 · Other (J): 30,549 (derivative) @ $0 · Other (J): 56,322 (derivative) @ $0 · Other (J): 50,000 (derivative) @ $0 | EDGAR |
| 2025-07-10 | 4 | SHEPLER ROBERT G — Director | Other (J): 16,860 (derivative) @ $0 · Other (J): 30,549 (derivative) @ $0 · Other (J): 56,322 (derivative) @ $0 · Other (J): 50,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | BAMFORD PASCAL — Chief Clinical Officer | Tax withholding (F): 670 @ $1.25 | EDGAR |
| 2025-04-03 | 4 | Ek John Frederick — CFO | Tax withholding (F): 16,432 @ $1.35 | EDGAR |
| 2025-03-25 | 4 | McKelligon Brian — President and CEO, Director | Tax withholding (F): 7,550 @ $1.70 | EDGAR |
| 2025-03-25 | 4 | Ramachandran Niro Ph.D — Chief Business Officer | Tax withholding (F): 2,310 @ $1.70 | EDGAR |
| 2025-03-04 | 4 | Kamocsay Jennifer — Chief Legal Officer | Tax withholding (F): 3,851 @ $1.63 · Tax withholding (F): 3,594 @ $1.63 | EDGAR |
| 2025-03-04 | 4 | Ek John Frederick — CFO | Tax withholding (F): 3,594 @ $1.63 | EDGAR |
| 2025-03-04 | 4 | BAMFORD PASCAL — Chief Clinical Officer | Tax withholding (F): 1,283 @ $1.63 · Tax withholding (F): 2,567 @ $1.63 | EDGAR |
| 2025-03-04 | 4 | Ramachandran Niro Ph.D — Chief Business Officer | Tax withholding (F): 2,310 @ $1.63 · Tax withholding (F): 3,594 @ $1.63 | EDGAR |
| 2025-03-04 | 4 | McKelligon Brian — President and CEO, Director | Tax withholding (F): 7,550 @ $1.63 · Tax withholding (F): 8,257 @ $1.63 | EDGAR |
Recent 8-K events — Akoya Biosciences, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-07-08 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-07 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-06-02 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-05-21 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-04-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-04-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-03-17 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-02-25 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=AKYA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →